3:03 PM
Jan 25, 2018
 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million.

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8 million shares at $35 in an upsized follow-on underwritten by BofA Merrill Lynch, Cowen, Leerink and Wedbush PacGrow. The price is a 6% discount to the company’s close of $37.25 on Tuesday, when it proposed to raise $150 million....

Read the full 352 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >